Fadi Haddad

Assistant Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Fadi Haddad is an Assistant Professor at The University of Texas MD Anderson Cancer Center, United States. His research primarily focuses on chronic myeloid leukemia, acute lymphoblastic leukemia, and the development of chemotherapy-free treatment regimens. He has published significant articles addressing treatment outcomes and management strategies in these hematological malignancies.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Lewis Nasr

The University of Texas MD Anderson Cancer Center

UNITED STATES

Fadi Haddad

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase

Mini-Hyper-CVD plus Venetoclax and Navitoclax for Relapsed/Refractory Acute Lymphoblastic Leukemia

Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements

SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Can Be Treated with Chemotherapy-Free Regimens without Transplant

Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm

Management of chronic myeloid leukemia in 2025

Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research

Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase

Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia

Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia

A phase 2 trial of mini‐hyper‐CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia

Characteristics and outcomes of patients with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia after failure of a frontline ponatinib‐containing therapy

The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia

Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase

Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin

Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia

Ponatinib‐review of historical development, current status, and future research

Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL

Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis

Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era

Reply to “Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!”

The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors

Moving away from chemotherapy in newly diagnosed Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia

Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1

Association between bariatric surgery and outcomes in chronic myeloid leukemia.

Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results

Treatment de-escalation in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens.

Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring.

Collaborators (15)

Lewis Nasr

Jayastu Senapati

Alex Bataller Torralba

Ghayas C. Issa

Rashmi Kanagal Shamanna

Sanam Loghavi

Koji Sasaki

Nitin Jain

Farhad Ravandi

Tareq Abuasab

Nicholas J. Short

Jennifer Croden

Elias J. Jabbour

Courtney D. DiNardo

Musa Yilmaz

Make your next move.